黑料网

听

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 黑料网 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

听

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 黑料网 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

听

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 黑料网 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

听

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 黑料网 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 黑料网 College Ave. Room 606

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

听

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.